CIMAvax-EGF quality assurance manager at the Centro de InmunologÃa Molecular (Center for Molecular Immunology)
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.